CN1771030A - 治疗帕金森病的方法 - Google Patents

治疗帕金森病的方法 Download PDF

Info

Publication number
CN1771030A
CN1771030A CNA200480009655XA CN200480009655A CN1771030A CN 1771030 A CN1771030 A CN 1771030A CN A200480009655X A CNA200480009655X A CN A200480009655XA CN 200480009655 A CN200480009655 A CN 200480009655A CN 1771030 A CN1771030 A CN 1771030A
Authority
CN
China
Prior art keywords
parkinson
disease
safinamide
composition
levodopa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480009655XA
Other languages
English (en)
Chinese (zh)
Inventor
F·鲁杰罗
C·卡塔内奥
P·萨尔瓦蒂
L·贝纳蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newron Pharmaceuticals SpA
Original Assignee
Newron Pharmaceuticals SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1771030(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharmaceuticals SpA filed Critical Newron Pharmaceuticals SpA
Priority to CN201110271872.8A priority Critical patent/CN102274517B/zh
Publication of CN1771030A publication Critical patent/CN1771030A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA200480009655XA 2003-04-11 2004-04-08 治疗帕金森病的方法 Pending CN1771030A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110271872.8A CN102274517B (zh) 2003-04-11 2004-04-08 治疗帕金森病的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11
US60/462,205 2003-04-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201110271872.8A Division CN102274517B (zh) 2003-04-11 2004-04-08 治疗帕金森病的方法

Publications (1)

Publication Number Publication Date
CN1771030A true CN1771030A (zh) 2006-05-10

Family

ID=33159845

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA200480009655XA Pending CN1771030A (zh) 2003-04-11 2004-04-08 治疗帕金森病的方法
CN201110271872.8A Expired - Lifetime CN102274517B (zh) 2003-04-11 2004-04-08 治疗帕金森病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201110271872.8A Expired - Lifetime CN102274517B (zh) 2003-04-11 2004-04-08 治疗帕金森病的方法

Country Status (28)

Country Link
US (3) US8283380B2 (enExample)
EP (2) EP2070526B1 (enExample)
JP (2) JP2006522800A (enExample)
KR (2) KR101129015B1 (enExample)
CN (2) CN1771030A (enExample)
AR (1) AR044007A1 (enExample)
AT (1) ATE435012T1 (enExample)
AU (1) AU2004228782B2 (enExample)
BR (1) BRPI0409364A (enExample)
CA (1) CA2523188C (enExample)
CY (3) CY1109295T1 (enExample)
DE (1) DE602004021790D1 (enExample)
DK (2) DK1613296T3 (enExample)
ES (2) ES2454272T3 (enExample)
FR (1) FR15C0054I2 (enExample)
HU (1) HUS1500043I1 (enExample)
IL (2) IL171331A (enExample)
LU (1) LU92782I2 (enExample)
MX (1) MXPA05010873A (enExample)
NL (1) NL300752I2 (enExample)
NO (3) NO334316B1 (enExample)
NZ (1) NZ542910A (enExample)
PL (2) PL2070526T3 (enExample)
PT (2) PT2070526E (enExample)
RU (1) RU2342929C2 (enExample)
SI (2) SI2070526T1 (enExample)
TW (1) TWI340640B (enExample)
WO (1) WO2004089353A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103284984A (zh) * 2006-06-19 2013-09-11 纽朗制药有限公司 生产2-[4-(3-和2-氟苄氧基)苄氨基]丙酰胺类的方法
CN101687773B (zh) * 2007-06-15 2014-07-30 纽朗制药有限公司 取代的2-[2-(苯基)乙氨基]烷酰胺衍生物及其作为钠和/或钙通道调节剂的应用
CN108349993A (zh) * 2015-08-27 2018-07-31 普雷克斯顿医疗股份公司 用于左旋多巴诱导的运动障碍疗法的脑-穿透剂色酮肟衍生物
CN111936128A (zh) * 2018-04-04 2020-11-13 神经生物遗传有限公司 脑卒中的预防或治疗用组合物
CN112279778A (zh) * 2019-11-28 2021-01-29 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
CN115003294A (zh) * 2019-11-12 2022-09-02 卢森堡大学 用于治疗或预防帕金森病症的产甲烷古细菌的含铁氢化酶抑制剂

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
ATE317280T1 (de) * 2001-09-03 2006-02-15 Newron Pharm Spa Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
PT1658062E (pt) * 2003-08-25 2010-03-31 Newron Pharm Spa Derivados de alfa-amino amida úteis como agentes antiinflamatórios
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
KR101277520B1 (ko) * 2004-09-10 2013-06-21 뉴론 파마슈티칼즈 에스. 피. 에이. （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
WO2007069274A2 (en) * 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
NZ567540A (en) * 2005-12-22 2010-07-30 Newron Pharm Spa 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
JP2010525018A (ja) * 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
US20090149544A1 (en) * 2007-10-22 2009-06-11 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
CN101896456B (zh) 2007-12-11 2014-10-22 纽朗制药有限公司 具有高纯度的2-[4-(3-或2-氟苄氧基)苄氨基]丙酰胺类的生产方法
EA019529B1 (ru) * 2007-12-19 2014-04-30 Ньюрон Фармасьютикалс С.П.А. Альфа-аминоамидные производные, применяемые в лечении психиатрических расстройств
US20110027354A1 (en) * 2008-04-01 2011-02-03 Kim Hyoung-Chun Anti-parkinsonian compounds
NZ589486A (en) * 2008-06-02 2012-08-31 Generics Uk Ltd A process for the preparation of enantiomerically pure 1-(R)-(2-propynylamino)indan
CA2723870C (en) * 2008-06-02 2015-04-21 Generics [Uk] Limited An improved process for the preparation of amines
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
CN102065687A (zh) * 2008-06-13 2011-05-18 泰华制药工业有限公司 雷沙吉兰用于改善帕金森氏症
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh) 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
KR101851118B1 (ko) 2010-04-27 2018-04-23 뉴론 파마슈티칼즈 에스. 피. 에이. 랄핀아미드 메탄설포네이트 염들 또는 이들의 ｒ―에난티오머들의 제조 방법
US9017723B2 (en) 2010-04-30 2015-04-28 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US10196341B2 (en) 2011-08-19 2019-02-05 The Trustees Of Princeton University C-halogen bond formation
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
MX390106B (es) 2012-10-22 2025-03-20 Merz Pharmaceuticals Llc Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson
NZ706590A (en) 2012-11-02 2016-02-26 Teikoku Pharma Usa Inc Propynylaminoindan transdermal compositions
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
US10111879B2 (en) 2013-06-27 2018-10-30 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
SG11201608608PA (en) * 2014-04-21 2016-11-29 Civitas Therapeutics Inc Rapid relief of motor fluctuations in parkinson's disease
US10676425B2 (en) 2014-10-02 2020-06-09 Megabiowood Co., Ltd Alpha-aminoamide derivative compound and pharmaceutical composition comprising same
KR102889062B1 (ko) * 2016-03-17 2025-11-21 더 존스 홉킨스 유니버시티 Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
WO2018132746A1 (en) * 2017-01-14 2018-07-19 Mischley Laurie Kathern Method of using human excrement and secretions for early detection of parkinson's disease
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
CA3072994A1 (en) * 2017-08-17 2019-02-21 Zi-Qiang Gu Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof
EA202091127A1 (ru) 2017-11-02 2020-09-22 Замбон С.П.А. Фармацевтические композиции, включающие сафинамид
CN119564619A (zh) * 2019-09-12 2025-03-07 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN112915083A (zh) * 2019-12-06 2021-06-08 上海医药集团股份有限公司 药物组合物、成套药盒及其应用
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院（石河子市技工学校） 一种葡萄酒洗浸奶酪加工方法
US20230181508A1 (en) * 2020-08-31 2023-06-15 Purdue Pharma L.P. Compositions and methods for levodopa delivery
KR20230154249A (ko) * 2021-03-08 2023-11-07 프로테나 바이오사이언시즈 리미티드 파킨슨 질환의 치료
KR102790040B1 (ko) * 2021-06-24 2025-04-01 연세대학교 산학협력단 도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
EP0331620B1 (de) 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US6258827B1 (en) * 1995-05-26 2001-07-10 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective NMDA antagonists
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103284984A (zh) * 2006-06-19 2013-09-11 纽朗制药有限公司 生产2-[4-(3-和2-氟苄氧基)苄氨基]丙酰胺类的方法
CN101687773B (zh) * 2007-06-15 2014-07-30 纽朗制药有限公司 取代的2-[2-(苯基)乙氨基]烷酰胺衍生物及其作为钠和/或钙通道调节剂的应用
CN108349993A (zh) * 2015-08-27 2018-07-31 普雷克斯顿医疗股份公司 用于左旋多巴诱导的运动障碍疗法的脑-穿透剂色酮肟衍生物
CN111936128A (zh) * 2018-04-04 2020-11-13 神经生物遗传有限公司 脑卒中的预防或治疗用组合物
CN111936128B (zh) * 2018-04-04 2022-08-12 神经生物遗传有限公司 脑卒中的预防或治疗用组合物
CN115003294A (zh) * 2019-11-12 2022-09-02 卢森堡大学 用于治疗或预防帕金森病症的产甲烷古细菌的含铁氢化酶抑制剂
CN112279778A (zh) * 2019-11-28 2021-01-29 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
CN112279778B (zh) * 2019-11-28 2021-11-30 北京兰晟医药科技有限公司 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物

Also Published As

Publication number Publication date
US8283380B2 (en) 2012-10-09
SI1613296T1 (sl) 2009-10-31
EP2070526B1 (en) 2014-02-26
WO2004089353A8 (en) 2005-09-01
CN102274517A (zh) 2011-12-14
PT2070526E (pt) 2014-03-31
WO2004089353A3 (en) 2004-12-16
ES2454272T3 (es) 2014-04-10
JP2006522800A (ja) 2006-10-05
IL216403A0 (en) 2011-12-29
JP2013067647A (ja) 2013-04-18
NO335537B1 (no) 2014-12-22
NO20131417L (no) 2005-12-09
DE602004021790D1 (de) 2009-08-13
EP1613296A2 (en) 2006-01-11
NO334316B1 (no) 2014-02-03
FR15C0054I1 (fr) 2015-11-09
CY1109295T1 (el) 2014-07-02
RU2005131422A (ru) 2006-04-27
FR15C0054I2 (fr) 2018-01-26
CA2523188A1 (en) 2004-10-21
CA2523188C (en) 2012-09-25
IL216403A (en) 2015-01-29
KR20060010745A (ko) 2006-02-02
RU2342929C2 (ru) 2009-01-10
KR101129015B1 (ko) 2012-04-20
PL2070526T3 (pl) 2014-08-29
MXPA05010873A (es) 2006-03-21
AU2004228782A1 (en) 2004-10-21
PL1613296T3 (pl) 2009-12-31
TWI340640B (en) 2011-04-21
US20130053368A1 (en) 2013-02-28
PT1613296E (pt) 2009-07-30
WO2004089353A2 (en) 2004-10-21
CY1115286T1 (el) 2017-01-04
AU2004228782B2 (en) 2010-05-20
US8901176B2 (en) 2014-12-02
CY2015025I2 (el) 2016-04-13
DK2070526T3 (da) 2014-03-24
US9492410B2 (en) 2016-11-15
CN102274517B (zh) 2018-08-31
LU92782I2 (fr) 2015-09-22
ATE435012T1 (de) 2009-07-15
BRPI0409364A (pt) 2006-04-25
HUS1500043I1 (hu) 2018-11-28
DK1613296T3 (da) 2009-10-05
NL300752I2 (enExample) 2016-07-05
CY2015025I1 (el) 2016-04-13
NO20054640L (no) 2005-12-09
US20070093495A1 (en) 2007-04-26
EP1613296B1 (en) 2009-07-01
IL171331A (en) 2012-03-29
TW200505423A (en) 2005-02-16
NO20054640D0 (no) 2005-10-10
NO2015018I2 (no) 2015-07-23
NZ542910A (en) 2007-10-26
AR044007A1 (es) 2005-08-24
NO2015018I1 (no) 2015-08-03
EP2070526A1 (en) 2009-06-17
US20150150833A1 (en) 2015-06-04
ES2326373T3 (es) 2009-10-08
KR20110070929A (ko) 2011-06-24
SI2070526T1 (sl) 2014-05-30

Similar Documents

Publication Publication Date Title
CN1771030A (zh) 治疗帕金森病的方法
JP6014702B2 (ja) 線維筋痛症候群の長期治療のためのミルナシプラン
KR100797603B1 (ko) 섬유근육통을 치료하기 위한 도파민 ｄ2/ｄ3 수용체작용제의 사용
JP2010526820A (ja) 気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物
CN101657193A (zh) 用于治疗纤维肌痛的屈昔多巴及其药物组合物
CN1726022A (zh) 用于治疗纤维肌痛及其相关疾病的普加巴林及其衍生物
CN1606442A (zh) 多动腿综合征的新疗法
CN1717235A (zh) 使用巴比土酸衍生物治疗运动障碍的方法
HK1087918A (en) Method for treatment of parkinson's disease
HK1161969B (zh) 治疗帕金森病的方法
HK1161969A (en) Methods for treatment of parkinson's disease
JP2002255820A (ja) モノアミン作動性神経の活性化剤
HK1072893A (en) New treatments for restless legs syndrome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1087918

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060510

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1087918

Country of ref document: HK